X

Clinical Trials

Contact Us

Rare Tumor

URCC 19075 **MBMC ONLY**

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)


A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia


URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting


S2013: I-CHECKIT

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study


A031702 (Penile Cohort Suspended 3/13/20, Miscellaneous GU Tract Variants Cohort suspended 7/20/20, Small Cell Carcinoma/ Neuroendocrine of the Bladder Cohort suspended 4/21/21, Adenocarcinoma of the Bladder Cohort Closed 11/9/20, Renal Medullary Cohort suspended 6/23/21, Sarcomatoid Renal Cell Carcinoma suspended 8/12/21, Cohort C: Squamous Cell Carcinoma of the Bladder temporarily suspended 4/7/22 )

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors


S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors


MATCH: EAY131 (NCT02465050)

MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.